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Abstract
Background: During androgen ablation prostate cancer cells’ growth and survival become independent of normal
regulatory mechanisms. These androgen-independent cells acquire the remarkable ability to adapt to the surrounding
microenvironment whose factors, such as neurotransmitters, influence their survival. Although findings are becoming
evident about the expression of a1A-adrenoceptors in prostate cancer epithelial cells, their exact functional role in
androgen-independent cells has yet to be established. Previous work has demonstrated that membrane lipid rafts
associated with key signalling proteins mediate growth and survival signalling pathways in prostate cancer cells.
Methodology/Principal Findings: In order to analyze the membrane topology of the a1A-adrenoceptor we explored its
presence by a biochemical approach in purified detergent resistant membrane fractions of the androgen-independent
prostate cancer cell line DU145. Electron microscopy observations demonstrated the colocalisation of the a1A-adrenoceptor
with caveolin-1, the major protein component of caveolae. In addition, we showed that agonist stimulation of the a1A-
adrenoceptor induced resistance to thapsigargin-induced apoptosis and that caveolin-1 was necessary for this process.
Further, immunohistofluorescence revealed the relation between high levels of a1A-adrenoceptor and caveolin-1 expression
with advanced stage prostate cancer. We also show by immunoblotting that the TG-induced apoptosis resistance described
in DU145 cells is mediated by extracellular signal-regulated kinases (ERK).
Conclusions/Significance: In conclusion, we propose that a1A-adrenoceptor stimulation in androgen-independent prostate
cancer cells via caveolae constitutes one of the mechanisms contributing to their protection from TG-induced apoptosis.
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Introduction
Prostate cancer is one of the most common forms of cancer in
men and the second cause of cancer death in industrialized
countries [1]. Various factors such as androgens and growth
factors regulate epithelial cell proliferation and apoptosis in the
normal prostate and early-stage prostate cancer (PCa). Androgen
ablation is currently the leading therapy used to block the growth
of androgen-dependent cancer cells. However PCa cells’ prolifer-
ation and survival often become independent of regulatory
mechanisms leading to a hormone-refractory disease [2] for which
there is currently no successful therapy. Androgen-independent
PCa cells have the remarkable ability to adapt to the surrounding
microenvironment whose influence on intracellular survival
pathways remains subject to debate [3]. Indeed, PCa cells are in
contact with various factors such as hormones, growth factors and
neurotransmitters which are thought to influence the physiology of
these cells. Among others, interest has been shown for the
endogenous catecholamines norepinephrine and epinephrine. In
fact, the subepithelial stroma of the prostate is particularly rich in
autonomic nerves and a1-adrenoceptors (a1-AR). The a1A-AR
subtype, in particular, is found in smooth muscle cells but its
expression has also been described in epithelial cells [4,5]. The
a1A-AR is a member of the superfamily of G-protein coupled
receptors (GPCR) mediating actions of the previously mentioned
catecholamines in a variety of cells [6].
a1-AR antagonists are already used for the clinical treatment of
benign prostate hyperplasia (BPH) [7], where their therapeutic
benefit is attributed to a direct action on a1-AR present in prostate
smooth muscle cells [8]. However, several studies have provided
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doxazosin on long-term BPH treatment. These agents have been
demonstrated to inhibit prostate growth by inducing apoptosis in
stromal and epithelial cells and are emerging as potential
therapeutic regimens for the prevention and treatment of
androgen-independent PCa [9,10,11]. In addition, previous
studies from co-workers on human prostate cancer epithelial
(hPCE) cells and the androgen-dependent prostate cancer cell line
LNCaP showed that phenylephrine (PHE), an a1A-AR agonist,
stimulates their proliferation [12,13]. Despite these promising
findings, the functional role of a1A-AR in androgen-independent
PCa cells has yet to be established.
It has been described that the signalling and trafficking of
several GPCR are regulated by specialized plasma membrane
domains known as lipid rafts [14]. Moreover, recent data on
cardiomyocytes have shown that a1-AR as well as the molecules
involved in its signal transduction pathway are accumulated in
caveolae, a subclass of membrane microdomains [15,16].
Caveolae are 50–100 nm flask-shaped plasma membrane invag-
inations, characterized on one hand by high contents of cholesterol
and glycosphingolipids and on the other hand by the presence of
caveolin-1 (cav-1), the major constitutive protein of 20–25 kD
[17]. Interestingly, cav-1 has been associated with many diseases
such as atherosclerosis and Alzheimer’s disease [18,19]. Regarding
its role in cancer, it has been established that PCa is associated
with increased cav-1 expression [20]. In fact, this protein has been
identified as a marker associated with PCa progression and
hormone-refractory disease, playing a determinant role in the
androgen-independence of PCa cells [21]. By its association with
specific receptors and enzymes on the plasma membrane, cav-1
can be a direct mediator of survival, growth and metastasis signals
in PCa cells [22].
To date, not much is known about the mechanisms underlying
neurotransmitters involvement in the survival of PCa cells, let-
alone the role of a1A-AR in androgen-independent epithelial cells
and PCa progression. In this regard, it is tempting to link the
presence of a1A-AR and cav-1 and to hypothesize that the a1A-AR
could mediate via caveolae its functional effects on growth or
survival of advanced stage PCa cells.
The objective of our work was therefore to explore the role of
the a1A-AR in androgen-independent PCa cells. Here, we
investigate the presence of a1A-AR in caveolae of DU145 cells,
an androgen-independent PCa cell line derived from brain
metastasis. We analyze the consequence of a1A-AR stimulation
by PHE on the receptor and cav-1 membrane distribution as well
as its effect on the lipid composition of membrane raft fractions
purified from DU145 cells. Furthermore, we describe the effect of
PHE in the apoptosis resistance of these cells through activation of
ERK and our results strongly imply the involvement of caveolae in
this signalling pathway. Finally, by immunohistofluorescence and
RT-PCR, we observe a positive correlation of a1A-AR and cav-1
expression and advanced stage PCa. The presence of a1A-AR-rich
caveolae could therefore contribute to the generalized apoptosis
resistance characterizing androgen-independent prostatic tissue.
Methods
Cell culture
The androgen-independent human prostate cancer cell line
DU145, obtained from the American Type Culture Collection,
was maintained in culture in RPMI 1640 medium (Life
Technologies, Inc) supplemented with 10% (v/v) FCS (Seromed,
Poly-Labo, Strasbourg, France), 5 mM L-glutamine and 2 mM
kanamycin (Sigma). Cells were routinely grown in 50 ml flasks
(Nunc, PolyLabo, Strasbourg, France) at 37uC in a humidified 5%
CO2-95% air atmosphere. These cells constitute a suitable model
for brain metastatic cancer cells present in hormone-refractory
prostate cancer.
Cell transfections and generation of cav-1 knock-down
DU145 cell line
Two ready-to-use siRNAs against a1A-AR (siADR1A, Euro-
gentec) were transiently transfected (50 nM) with HiPerfect
Transfection Reagent (Qiagen) in DU145 cells. Control siRNA
(siCTL) experiments were performed by transfecting siRNA
against Luciferase.
siLuciferase (siCTL) : 59-CUUACGCUGAGUACUUCGA-39.
siADR1A-1 (mix of): 59-CAGGAAAGAUGCAGAGGA-39 and
59-UUCCUCUGCAUCUUUCCU-39. siADR1A-2 (mix of): 59-
GCGUCUACGUGGUGGCCA-39 and 59-UUGGCCACCAC-
GUAGACG-39.
Stable cell lines were obtained by transfecting DU145 cells with
a Psuper vector encoding short hairpin RNA (shRNA) against cav-
1 (sequence: CTGGAATAAGTTCAAATTCTT 2121 39utr)
(DUshcav-1) (or empty Psuper vector for control cell line,
DUshCTL) using Nucleofector, as recommended by the manu-
facturer (Amaxa GmbH, Ko ¨ln, Germany). We transfected 2610
6
trypsin-treated DU145 cells with 3 mg of vector and then used the
transfected cells to seed a 24 well plate (Nunc) at very low density.
Clones underexpressing cav-1 were selected on the basis of their
antibiotic resistance to puromycine and validated by Western Blot.
Antibodies and Reagents
Primary antibodies used for immunofluorescence (IF) micros-
copy and immunoblotting (IB) were: (1:100) rabbit anti-a1A
adrenoceptor (Santa Cruz Biotechnology), (1:100) rabbit anti-
caveolin-1 (Santa Cruz Biotechnology), (1:50) mouse anti-caveolin-
1 (BD transduction Laboratories), (1:400) mouse anti-b-actin
(Sigma), (1:200) anti-calnexin (Chemicon, Millipore, Paris,
France), (1:1000) mouse anti-cytokeratin 18 (Chemicon, Millipore,
Paris, France), (1:1000) rabbit anti-PARP (Cell Signaling), (1:100)
mouse anti-bax (6A7) (Santa Cruz Biotechnology) recognizing an
exposed epitope of bax in the activated conformation, (1:1000)
rabbit anti-procaspase 3 (UPSTATE), (1:1000) anti-phospho-p44/
42 MAP Kinase and (1:1000) anti-p44/42 MAP Kinase (Cell
Signaling). Secondary antibodies used for IB were: (1:10000)
horseradish peroxidase-linked anti-mouse or anti-rabbit (Chemi-
con). For IF, we used (1:1000) Alexa FluorH 488-labelled and
(1:2000) 546-labelled secondary antibodies (Molecular Probes).
Cells were treated with 10 mM L-Phenylephrine Hydrochloride
(PHE), 1 mM prazosin (PRA) and 10 mM PD98059 for three days
(renewed every 24 h) and 10 mM Thapsigargin (TG) for 48 hours
in RPMI medium. Short term PHE treatments were realized in a
solution containing (mM): NaCl, 116; KCl, 5.6; CaCl2, 1.8;
MgCl2, 1.2; NaHCO3, 5; NaH2PO4, 1; HEPES, 20; pH 7.3. All
chemical products were provided by Sigma except TG (Alomone)
and PD98059 (Calbiochem).
Cell cycle analysis
Cells were grown in three 60-mm dishes per condition and
drugs were applied as described above. After treatments, cells were
trypsinized, harvested and resuspended in 0.2 ml sterile PBS. 1 ml
of cold 70% ethanol was added onto cell suspensions while
vortexing. Samples were centrifuged, washed in sterile PBS and
then incubated with ribonuclease (2 mg/ml) for 15 min. Propidium
iodide (25 mg/ml final in PBS-triton X-100 0.1%) was then added
and allowed to incubate for an additional 30 min. DNA content
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measuring the emission at 520 nm (FL3) using a flow cytometer
(Beckman coulter Epics XL4-MCL with Expo32 acquisition).
Experiments were repeated four times.
Western Blot
The cell culture medium was discarded and flasks were washed
with iced PBS. Cellular proteins were then extracted using RIPA
buffer [1% (v/v) Triton X-100, 1% (w/v) Na deoxycholate,
150 mM NaCl and 20 mM sodium or potassium phosphate,
pH 7.2] with 5 mM EDTA and anti-proteases cocktail (P8340;
Sigma) for 30 min on ice. After scraping, any insoluble material
was removed by centrifugation at 300006g for 10 min at 4 uC and
the amount of protein was assessed by the BCA method (Pierce
Chemical Company, Rockford, IL, U.S.A.). Equal amounts of
proteins were subjected to SDS/PAGE (16% gels). Finally, the
proteins were transferred on to nitrocellulose membranes using a
semi-dry electro-blotter (Bio-Rad). After 1 h saturation in 5% non-
fat milk (or 5% BSA (bovine serum albumin) only for anti-
phospho-p44/42 MAPK), membranes were incubated overnight
with diluted primary antibodies (see ‘‘Antibodies and Reagents’’).
The membranes were then washed (3610 min) with a TNT buffer
(15 mM Tris/HCl, pH 8, 140 mM NaCl and 0.05% Tween 20)
and treated with the corresponding horseradish peroxidase-linked
secondary antibodies (anti-mouse or anti-rabbit, Pierce), (1:10000)
diluted in TNT/milk (or TNT/BSA) for 1 h at room temperature.
After several washes in TNT buffer, the membranes were
processed for chemiluminescent detection using the Super Signal
West Dura chemiluminescent substrate (Pierce) according to the
manufacturer’s instructions. The membranes were finally exposed
to X-Omat AR films (Eastman Kodak Company, Rochester, NY,
U.S.A.). The intensity of the signals was evaluated by densitometry
and semi-quantified using the ratio for each sample between the
intensity of protein of interest divided by the actin or calnexin
intensity. Each experiment was repeated at least twice.
Isolation of Detergent Resistant Membranes (DRM) and
Dot blot
Cells were rinsed, scrapped, centrifuged and the supernatant
was removed. The pellet was resuspended with isolation buffer B
(according to Axis-Shield S33 Application Sheet) and homoge-
nized with a Dounce homogenizer (Kontes) of 15 mm pestle
clearance then centrifuged for 10 min at 10006g. The supernatant
corresponding to crude lipid raft extract was isolated and 0.2%
Triton X-100 was added. A discontinuous 5-step OptiprepH (Axis-
Shield PoC AS) gradient was formed with buffer D (buffer B+1%
Triton X-100) (w/v) in order to obtain 1.66 ml of 35%; 2.5 ml of
20%; 2.5 ml of 15%; 2.5 ml 10%; 0.83 ml of 5%. Crude lipid raft
extract was made dense with sucrose (230 mg for 0.5 ml of lysate)
and laid at the interface between gradients 35% and 20%.
Ultracentrifugation at 1654006g for 4 h at 4uC in 50 Ti rotor
(Beckman Coulter) was followed by collection from the bottom up
of 1.1 ml fractions. 1.1 ml of 20% (v/v) TCA (Trichloroacetic
Acid) was added to each fraction in order to precipitate proteins.
Tubes kept on ice for 20 min were centrifuged at 100006g at 4uC
for 10 min. The precipitate was washed with methanol, centri-
fuged then re-suspended in 4% (v/v) SDS. Since samples were not
highly concentrated in proteins and detection by classical western
blot was difficult to obtain, samples were loaded on nitrocellulose
membrane in a 96-well Dot-Blot unit according to the manufac-
turer’s instructions (Bio-Rad). Briefly, the ten fractions were
spotted onto nitrocellulose membrane in series. When dry, the
membrane was incubated in blocking solution for 1 h (TNT/milk)
then hybridized with the desired antibodies following classical IB
procedure as described above (see ‘‘Western Blot’’). Precautions
were accordingly taken in keeping some important factors constant
for the treated and non-treated conditions. The cell density used
for the experiments was constant and when cold detergent
extraction was carried out both the concentration of the detergent
and the ratio of cell number/detergent concentration were the
same. Each well was loaded with 25 ml from each fraction. This
standardized method was repeated at least three times and was
used to evaluate changes in the partitioning of a target molecule in
DRM, avoiding false estimations when based on the relative
amounts with regard to all other molecules present.
Quantification of phosphatidylcholine (PC) and
sphingomyelin (SM)
Lipids were extracted according to the method of Folch et al.
[23]. Dimyristoylphosphatidylcholine (DMPC Sigma), dimyris-
toylphosphatidylserine (DMPS Avanti Polar Lipids), lauroylsphin-
gomyelin (LSM Avanti Polar Lipids) were used as internal
standards. Phospholipid analysis was performed on a Hypersil Si
26200 mm column (Agilent Technologies, Massy, France)
following protocol [24]. Positive ESI-MS was performed on a
MSD 1100 Mass Spectrometer (Agilent Technologies). The orifice
voltage was set at 120 V, the capillary voltage at 3.5 kV, the
drying gas (Nitrogen) flow at 8 l/min and scan range from m/z
400 to 950. Integrated peak were as from Extracted Ion
Chromatograms (EIC) for m/z=700 to 950 at the retention time
(RT) of PC, PS, SM were divided by the EIC for m/z=679 at the
RT of DMPC, m/z=681 at the RT of DMPS or m/z=647 at the
RT of LSM. Levels were determined by comparison of this ratio
with a standard curve of known amounts of phosphatidylcholine
and sphingomyelin.
Quantification of Cholesterol
Extraction and saponification were performed according to the
previously described procedure [25] with some modifications.
Quantification of cholesterol was performed using a HP6890 Gas
Chromatograph equipped with an HP7683 Injector and a
HP5973 Mass Selective Detector (Agilent Technologies). Chro-
matography was performed using a HP-5MS fused silica capillary
column (30 m60.25 mm inner diameter, 0.25 mm film thickness,
Agilent Technologies). A selected ion-monitoring program was
used for mass spectrometry. The ions used for analysis (m/z) were
as follows: epicoprostanol, 370; cholesterol, 368. Calibration
curves were obtained by analyzing standards prepared from
authentic standards (Steraloids) and extracted with the method
used for samples.
The above quantification protocols for lipids and cholesterol
were repeated three times for three individual experiments in non-
treated (control) and treated DU145 cells with PHE for 10 min. As
the amounts of lipids and cholesterol quantified in each fraction
(ng/ml or mg/ml) varied slightly among experiments, results were
normalised by determining mean values for the three experiments
represented by the percentage of lipid and cholesterol in each
fraction in control conditions compared to PHE-treated condi-
tions.
Plasma Membrane ‘‘Rip Off’’
This method was based on a published protocol [26]. Cells were
grown on glass coverslips. FormvarH-coated copper grids (accord-
ing to [27]) were coated with polylysine. Coverslips were placed
cell side down onto the grids and a slight pressure was exerted
using a rubber bung then coverslips were turned over and the grids
were carefully detached then fixed in 8% (v/v) PFA (paraformal-
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glycine/donkey serum immunolabelling was carried out according
to standard techniques, using primary antibodies followed by
species-specific anti-IgG gold conjugates of 6 nm, 12 nm and
18 nm. Finally, grids were contrasted and prepared for observa-
tion on a Hitachi H-600 transmission electron microscope
(magnification 620000) at 75 kV.
Ultrastructural Microscopy
For transmission electron microscopy, Cells were fixed in 2.5%
glutaraldehyde prepared in 0.1 M cacodylate buffer and post-fixed
in 1% osmium tetroxide in the same buffer. After acetonitril
dehydration, the pellet was embedded in Epon. Serial thin sections
(90 nm) were cut using a Reichert Ultracut E ultramicrotome and
collected on 150 mesh hexagonal barred copper grids. After
staining with 2% uranyl acetate prepared in 50% ethanol and
incubation with a lead citrate solution, sections were observed on a
Hitachi H-600 transmission electron microscope.
Indirect Immunofluorescence
Resection BPH specimens from human prostate frozen in liquid
nitrogen-cooled isopentane and kept in ‘‘Tissue-TekH’’ at 280uC
before 10 mm sections were prepared at 220uC with a cryostat,
mounted on glass slides and proceeded to IF study. Normal and
cancerous prostate tissues were supplied by tissue-array slides
(SuperBioChips Laboratories), deparaffinized according to man-
ufacturer’s indications (Cliniscience) before preparation for IF
according to [28]. Briefly, all slides were blocked during 30 min
with PBS/1.2% (v/v) gelatin then incubated with desired primary
antibodies for 1 h at 37uC then secondary antibodies (1 h, 37uC).
Imaging was performed using Zeiss LSM 510 confocal head (Carl
Zeiss) connected to a Zeiss Axiovert 200 M microscope with a640
oil-immersion objective lens (numerical aperture 1.45). Slides were
scanned using an argon ion laser and a helium/neon ion laser. All
scanning parameters were kept constant throughout the different
experiments. AIM 3.2 confocal microscope software (Carl Zeiss)
was used for data acquisition and analysis.
RT-PCR
Reverse transcription-PCR was carried out as previously
described [29]. The 178 pb a1A-AR isoform 1 amplicon was
amplifiedwith59-AGACCAATCCTCCTGTACCAC-39(forward)
and 59-CTCTGCATCTTTCATGTCCTAG-39 (reverse). The
220 pb cav-1 amplicon was amplified with 59-AGTGCTCCTGT-
TCTCCCTTC-39 (forward) and 59-CTTGTCGATGGCTTCC-
TTCAC-39 (reverse) (Eurogentec). The 236 pb GAPDH amplicon
internal control was amplified with 59-TTCACCACCATGGA-
GAAGGC-39 (forward) and 59-GGCATGGACTGTGGTCAT-
GA-39 (reverse). The 241 pb cytokeratin 18 amplicon was amplified
with 59-TGAGTCAGAGCTGGCACAGA-39 (forward) and 59-
TGGTGTCATTGGTCTCAGACA-39 (reverse). Finally, the
210 pb cytokeratin 14 amplicon was amplified with 59-TGCGA-
GATGGAGCAGCAGAA-39 (forward) and 59-TGCCATCGTG-
CACATCCATGA-39 (reverse). a1A-AR, cav-1, cytokeratin 14 and
18 mRNA expressions were validated by gel density analysis by
using GAPDH mRNA as internal control.
Human Tissue specimens
Human BPH biopsies were obtained from consenting patients
following the local ethical considerations. All experiments
involving patient tissues were carried out under approval number
‘CP 01/33’, issued by the ‘Comite ´ Consultatif de Protection des
Personnes dans la Recherche Biome ´dicale de Lille’.
Statistical analysis
Results were expressed as the mean6SEM. Statistical analysis
was performed using unpaired t tests (for comparing two groups) or
analysis of variance tests followed by Dunnett (for multiple control
versus test comparisons). Differences were considered significant
when p,0.05 (*), p ,0.01 (**) and p ,0.001 (***).
Results
a1A-AR is associated with cav-1 at the DU145 cell surface
Previous studies have described a direct interaction of a1A-AR with
cav-1 [15]. Moreover, a1A-AR signalling is known to localize in
caveolae [14,30]. To explore the membrane topology of a1A-AR, we
used the ‘‘rip-off’’ technique developed in adherent cells allowing the
isolation and observation by electron microscopy of large areas of the
plasma membrane [26]. a1A-AR immunogold staining (6 nm dots,
black arrowhead) colocalizes with cav-1 (18 nm dots, white arrowhead)
in plasma membrane microdomains of about 50–100 nm (Figure 1).
Figure 1. a1A-AR and cav-1 colocalization in DU145 cell surface.
Plasmamembranes were ‘‘ripped-off’’as described in the‘‘Methods’’section
and incubated with anti-cav-1 and anti-a1A-AR antibodies. Secondary
antibodies coupled with 6 nm and 18 nm gold particles were used against
anti-a1A-AR (black arrowhead) and anti-cav-1 (white arrowhead) respective-
ly. Grids were then processed for electron microscopy observation.
Colocalization of both proteins is indicated by circles. Bar, 200 nm.
doi:10.1371/journal.pone.0007068.g001
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composition alterations in DRM fractions induced by
phenylephrine
Analysis of plasma membrane microdomains, caveolae or lipid
raft composition typically begins with detergent solubilization of
whole cells followed by density gradient centrifugation and
recovery of DRM from light fractions of the gradient. We
investigated the association of a1A-AR with purified DRM from
DU145 whole cell membrane extracts on an OptiPrepH density
gradient. For the characterisation of DRM fractions, the presence
of a specific plasma membrane marker pan cadherin was first
assessed as a positive control (Figure 2A, a). Its presence in all 10
purified fractions demonstrates that the isolated DRM fractions
correspond to plasma membrane regions. In addition, the nuclear
protein PCNA (proliferation cell nuclear antigen) and the
mitochondrial protein bax were used as negative controls as they
are known not to associate with plasma membrane. Their absence
in DRM fractions validates the absence of contamination by
intracellular membranes (Figure 2A, a).
In order to determine whether previously defined microdomains
are involved in the a1A-AR signalling pathway in DU145 cells, we
examined a1A-AR stimulation by its specific agonist phenylephrine
(PHE). Dot blot analysis of DRM fractions revealed distribution of
cav-1 in low density gradient (5%–20%) fractions 1–6 and a1A-AR
in fractions 1 and 3–6 in control (CTL) conditions. After 10
minutes treatment by 10 mM PHE cav-1 distribution was observed
in low density gradient (5%–10%) fractions 1–5 and a1A-AR was
now detected in all fractions 1–6 (including low density fraction 2)
(Figure 2A, b, upper panel CTL; lower panel PHE). Importantly,
Gaq11 (an a1A-AR effector) contents showed a shift from fractions
4–5 to fractions 1 to 5 after PHE treatment and remain present in
higher density fractions, suggesting that receptor activation does
not involve all Gaq11 proteins present at the membrane level. We
also assessed the purinergic receptor P2Y2 used as a negative
control for the specificity of modification in protein distribution
induced by PHE. a1A-AR and P2Y2 are both GPCR sharing
similar signalling pathways. P2Y2 is located in the same fractions
whether DU145 cells were treated or not (Figure 2A, b, CTL and
PHE), therefore demonstrating the specificity of the previously
observed PHE-induced modified protein distribution.
Moreover, we were interested in the lipid composition of
purified DRM fractions. Lipids known to be enriched in biological
lipid rafts, such as lysophosphatidylcholine (LPC), sphingomyelin
(SM), phosphatidylcholine (PC) and cholesterol [31,32], were
analyzed. Once again, we investigated possible alterations of the
lipid composition of DRM fractions after PHE stimulation. Our
observations show a significant increase in the quantities of these
lipids mainly in low density gradient (5%–10%) fractions 1–5 as a
result of PHE stimulation (Figure 2B, a, b, c, d). These results are
in agreement with the well established fact that the high lipid
content causes floating of lipid microdomains in low density
fractions during centrifugation. Previously published data on lipid
model systems show that the size of lipid rafts depends on the lipid
membrane composition [33,34]. The observed alterations in lipid
compositions due to membrane reorganization may account for
lighter density microdomains resulting in the redistribution of a1A-
AR, cav-1 and Gaq11 observed within DRM fractions.
Protein and lipid reorganization induced by
phenylephrine is associated with cav-1-rich membrane
clustering
It is thought that upon extracellular stimulus, the plasma
membrane is prepared for the formation of more stabilized
domains and molecular clusters with enhanced size and lifetime
such as caveolae [35,36]. In order to understand the involvement
of caveolae in the a1A-AR signalling, we explored the effect of
PHE stimulation on the DU145 cell surface morphology
(Figure 3A). Cells treated for 10 min with 10 mMP H Ep r e s e n t
numerous surface invaginations corresponding to caveolae
(Figure 3A, b) as compared to non-treated cells (Figure 3A, a).
Caveolae are evident as circular profiles with uniform shape and
50–80 nm diameter. In this representative electron micrograph
caveolae are present as single pits (Figure 3A, b, black
arrowheads) and sometimes in more complex arrangements
interconnected with cytoplasmic caveolar profiles (Figure 3A, b,
white arrowheads).
Caveolae are formed by the polymerisation of caveolins leading
to the clustering and invagination of existing cholesterol-
sphingolipid rich domains in the cell plasma membrane [36].
We investigated the membrane distribution of cav-1 and a1A-AR
in control conditions and after a1A-AR stimulation (Figure 3B).
The same surface areas of preparations (ten/condition) were
compared in control and treated conditions and the mean number
of clusters was calculated (Figure 3B, d). Here, representative
electron micrographs for each condition are presented. We
observed a greater number of cav-1-rich domains in PHE treated
cell surfaces (Figure 3B, b) as compared to control conditions
(Figure 3B, a). Further, in order to test the specificity of PHE
stimulation on cell surface distribution of cav-1 and a1A-AR, we
used an a1-AR antagonist, prazosin (PRA) simultaneously with
PHE (Figure 3B, c). Cav-1 was present in isolated units and not in
clusters at the cell surface associated with a1A-AR. It should be
noted that PRA alone did not affect membrane localization of
either cav-1 or a1A-AR (data not shown). Our results propose that
a1A-AR may associate with cav-1 in resting cells and upon
receptor stimulation clustering of cav-1-rich units form a1A-AR-
containing structural surface caveolae.
Phenylephrine sensitizes DU145 cells’ resistance to
Thapsigargin-mediated apoptosis through the caspase-3
pathway in a cav-1 dependent manner
We first quantified cav-1 in DU145 non-transfected cells
(DU145 WT) and in stably transfected DU145 cells with either
an empty plasmid (DUshCTL) or a plasmid expressing shRNA
against cav-1 (Figure 4A, a). These cav-1 knockdown cells express
60% less cav-1 than non-transfected or shCTL cells. The use of
these cells allowed us to investigate the involvement of caveolae in
the a1A-AR signalling as it is further explained.
In order to study the role of a1A-AR signalling in the survival of
DU145 cells, we induced cell apoptosis by a 48 h treatment with
10 mM thapsigargin (TG), a known inhibitor of sarcoplasmic/
endoplasmic reticulum calcium ATPase (SERCA). As a conse-
quence of inhibiting SERCA, TG induces a substantial depletion
of calcium stores, creating perturbations in cellular calcium known
as reticular stress coupled with the ability to engage mitochondrial-
dependent apoptotic pathways [37]. In the present study,
apoptosis was measured as an increased number of cells in SubG1
phase of the cell cycle [38]. It should be noted that the percentage
of apoptotic cells in non-treated conditions was close to 0% and a
48 h TG treatment induced an increase of cells in SubG1 phase to
about 20% (Supporting Information, Figure S1). In order to assess
the effect of PHE on the TG-induced apoptosis, here we
considered TG-treated cells as 100% in SubG1 phase (Figure 4A,
b) and different treatments were therefore compared to TG-
treated conditions.
A three-day pre-treatment by 10 mM PHE prior to TG
treatment induced a significant 25% decrease in the number of
Prostate a Adrenergic Caveolae
PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7068Figure2.Proteinandlipidredistributions afteragoniststimulationofthe a1A-ARbyphenylephrine.(A)DRMfractionsofincreasingdensity
(from fraction 1 to 10) obtained as indicated in ‘‘Methods’’ section and analyzed by Dot blot. (a) Pan cadherin was used as a positive control confirming
that the fractions obtained correspond to plasma membrane. PCNA (proliferation cell nuclear antigen) and Bax were used as negative controls, their
absence confirming the non-contamination of DRM fractions by intracellular proteins known not to be associated with rafts. (b) Dot blot of the DRM
fraction collection in control condition (CTL) and 10 min treatment with 10 mM phenylephrine (PHE). Purinergic receptor P2Y2 was used as a negative
control for the specificity of the effect of phenylephrine on protein redistribution in fractions. Black rectangle marks the shift of a1A-AR, cav-1 and Gaq11
protein to lighter density fractions. (B) Lipid composition of the 10 fractions was quantified as described in the ‘‘Methods’’ section in control (black
column) andPHE treated cells (grey columns) for (a) lysophosphatidylcholine (LPC), (b) phosphatidylcholine (PC), (c) sphingomyelin(SM), (d)cholesterol.
Error bars represent SEM calculated from three independent experiments. Statistical analysis used the t test; *, p,0.05, **, p ,0.01 and ***, p ,0.001.
doi:10.1371/journal.pone.0007068.g002
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decrease in DUshCTL (black columns) (Figure 4A, b). In order to
demonstrate the a1-AR specificity of the apoptosis resistance
induced by PHE, PRA was simultaneously used with PHE.
Indeed, the resistance to TG-induced apoptosis was abolished
when 1 mM PRA was added to the pretreatment solution
(Figure 4A, b, black and white columns). It should be noted that
PHE or PRA alone have no effect on cell cycle phases (Supporting
Information, Figure S1, D). We then sought to investigate the
involvement of caveolae in this phenomenon. We therefore
disrupted caveolae structure by underexpressing cav-1. Analysis
of SubG1 phase revealed that in cav-1 knockdown cells PHE pre-
treatment did not promote resistance to TG-induced apoptosis
(Figure 4A, b, grey columns). All these results were confirmed by
the Hoechst staining (Supporting Information, Figure S2). The
present findings strongly suggest the involvement of caveolae in the
resistance to TG-induced apoptosis mediated by PHE in DU145
cells.
We then explored the expression of target proteins known to
regulate mechanisms of apoptosis induction or resistance such as
the caspases and the poly (ADP-ribose) polymerase (PARP) by
western blot analysis (Figure 4B, a). Scanning densitometry
allowed us to represent relative average densities of three different
experiments by histograms (Figure 4B, b, c and d). We first
assessed the expression of the 32 kD protein procaspase 3 in
DU145 WT, DUshCTL and DUshcav-1 cells (Figure 4B, a). Our
results in DU145 WT and DUshCTL cells showed a decrease of
procaspase 3 after TG treatment due to its cleavage to active
Figure 3. Cell surface modification and caveolin-1 mobilization following a1A-AR stimulation. (A) Representative electron micrograph of
DU145 cells in (a) non-treated condition (b) after 10 min treatment by 10 mM PHE. Caveolae and caveolin containing vesicles of 50–80 nm diameter
are dense in electrons are indicated by black arrowheads. White arrowheads indicate complex shaped caveolae. Bar, 500 nm. (B) Representative
electron micrograph of plasma membrane ‘‘ripped-off’’ from (a) non-treated cells, (b) treated for 10 min with 10 mM PHE alone and (c) PHE in the
presence of 1 mM PRA. 6 nm gold particles represent anti-a1A-AR labelling (black arrowheads) and 12 nm particles represent anti-cav-1 (white
arrowheads). Bar, 200 nm. (d) The area of randomly selected negatives of electron micrographs (ten/condition) was measured at a magnification of
20000. The number of cav-1 and a1A-adrenoceptor-containing clusters (minimum 3 gold particles for each protein) was counted (mean 6 SEM).
doi:10.1371/journal.pone.0007068.g003
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PLoS ONE | www.plosone.org 7 September 2009 | Volume 4 | Issue 9 | e7068Figure 4. Apoptosis resistance of DU145 cells depends on caveolin-1 expression and is mediated by the caspase-3 pathway. (A)(a)
Western blot showing the expression of caveolin-1 (cav-1) in DU145 cells stably transfected with Psuper plasmid expressing shRNA against cav-1
(DUshcav-1) and with empty Psuper plasmid (DUshCTL). Images are grouped from different lanes of the same gel and numbers above gels indicate
relative expression assessed on actin expression. (b) Cells were treated during 48 hrs with 10 mM Thapsigargin (TG) for induction of apoptosis,
preceded by a 3-day renewable treatment with 10 mM phenylephrine alone (PHE+TG) or simultaneously with prazosin (PRA+PHE+TG), then analyzed
by flow cytometry of propidium iodide-stained nuclei. Experiments were carried out in DU145 non-transfected cells (DU145 WT, white columns),
DUshCTL cells (black columns) and DUshcav-1 cells (grey columns). Error bars represent SEM calculated from four independent experiments.
Statistical analysis used t test; *, p,0.05, **, P,0.01. (B)(a) Expression levels of pro-caspase 3 and PARP (full-length and cleaved fragment) in DU145
WT, DUshCTL and DUshcav-1, after treatments indicated above were determined by western blot analysis and analyzed by scanning densitometry
using actin immunoblotting (for procaspase-3) and calnexin (for cleaved PARP) as internal controls. (b, c, d) Average densitometries are represented
by histograms for non-transfected (white columns), control shRNA (black columns) and caveolin-1 shRNA expressing cells (grey columns). Plots are
the average cumulative data (mean 6 SEM) of three experiments. Statistical analysis used the t test; *, p,0.05, **, p ,0.01 and ***, p,0.001.
doi:10.1371/journal.pone.0007068.g004
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indicated respectively by a 60–80% decrease in intensity
represented by the average ratios (Figure 4B, b, white and black
columns). The TG-induced decrease of procaspase 3 was reversed
by 60% and 134% respectively when DU145 WT and DUshCTL
cells were pre-treated with 10 mM PHE, indicating decreased
apoptosis (Figure 4B, a and c, white and black columns). Further,
when 1 mM PRA was used simultaneously with PHE, procaspase 3
levels were similar to TG alone pointing out the antagonistic
action of PRA to PHE (Figure 4B, a and c, white and black
columns). On the contrary, in DUshcav-1 cells, PHE alone or in
the presence of PRA did not reverse the 66% decrease of
procaspase 3 induced by TG (Figure 4B, a and c, grey columns).
PARP, a 116 kD nuclear poly (ADP-ribose) polymerase is one of
the main cleavage targets of caspase-3 in vivo [39]. Cleavage
separates the PARP amino-terminal DNA binding domain (24 kD)
from the carboxy-terminal catalytic domain (89 kD) [40] and
serves as a marker of cells undergoing apoptosis [41]. In all our cell
lines, TG treatment induced cleavage of PARP (Figure 4B, a),
revealed by an antibody which recognizes both the full-length 116
kD fragment as well as the 89 kD cleaved fragment (see the
‘‘Methods’’ section). A three-day treatment by 10 mM PHE
preceding TG reduced the amount of cleaved PARP by 30%
and 35% suggesting decreased apoptosis in DU145 and DushCTL
cells respectively (Figure 4B, a and d, white and black columns).
1 mM PRA pretreatment opposed the PHE-induced decrease in
PARP cleavage only in DU145 and DUshCTL cells (Figure 4B, a
and d, white and black columns). In Dushcav-1 cells, PHE
treatment with or without PRA had no effect in PARP cleavage as
compared to TG alone (Figure 4B, a and d, grey columns) once
again strongly suggesting the involvement of caveolae in this
function of a1-AR.
TG-induced apoptosis resistance in DU145 cells is also
mediated by a Bcl-2 family protein in a cav-1 dependent
manner
Bax is a 23 kD pro-apoptotic protein, member of the Bcl-2
family. The critical events in the activation process of Bax are: its
translocation to mitochondria and its N-terminal conformational
change closely coupled to mitochondrial membrane insertion and
oligomerisation [42,43]. The insertion of Bax into the mitochon-
drial outer membrane is closely associated with the release into the
cytosol of several proteins such as cytochrome c and procaspase-3
which are essential to the execution of the apoptotic program [44].
We investigated Bax activation by immunofluorescence using an
antibody which specifically recognizes the activated conformation
of Bax (see ‘‘Methods’’ section). The figures shown here are
representative of all slides observed. TG treatment of DU145 WT
(Figure 5A, b), DUshCTL cells (Figure 5B, b) and Dushcav-1 cells
(Figure 5C, b) induced an increase in activated-Bax staining as
compared to non-treated conditions (Figure 5A, B and C, a). In
DU145 and DushCTL cells, a three-day treatment by 10 mM
PHE preceding TG reduced activated-Bax expression (Figure 5A
and B, c) as compared to TG treatment alone (Figure 5A and B, b)
suggesting decreased apoptosis in these conditions. Once more,
1 mM PRA pretreatment opposed the PHE-induced decrease in
activated-Bax staining (Figure 5A and B, d). No significant
consequence of PHE pretreatment (with or without PRA) in the
resistance to TG-induced apoptosis was observed in DUshcav-1
cells (Figure 5C, b, c and d) once again strongly suggesting the
involvement of caveolae in this function of a1-AR. DAPI-stained
nuclei are indicative of the number of cells present in the
observation field. The absence of apoptotic figures (chromatin
condensation and nuclear fragmentation) in cells expressing
activated Bax is expectable as Bax activation is an early-stage
apoptotic process as opposed to nuclear fragmentation.
Expression and localization variations of cav-1 and a1A-
AR are associated with pathological alterations of human
prostate tissue
The a1A-AR is abundant in the fibromuscular tissue in normal
and hyperplastic prostates [45,46] however, its role in prostate
epithelial cells is still not well defined. Moreover, cav-1 has been
described to play an important role in the survival/growth of PCa
cells contributing to their metastatic activities [47,48]. To
determine the association of a1A-AR and cav-1 expression with
established features of PCa as well as BPH in comparison to
normal prostate, we performed a1A-AR and cav-1 immunostain-
ing on tissue microarrays containing specimen cores from 40
patients. Cytokeratin 18 immunostaining was used as a label of
apical epithelial cells present in acini. Normal tissue regions from 9
of these patients were present on these slides. The figures shown
here are representative of all samples observed. We first confirmed
the specificity of the a1A-AR antibody by the use of two siRNA
against a1A-AR (siADR1A-1 and siADR1A-2) (Figure 6A, a). The
use of these siRNA induced a 40% and 60% decrease of a1A-AR
as compared to DU145 cells transfected with the control siRNA.
Previous studies revealed that cav-1 overexpression is associated
with aggressive PCa [49] but little is known about a1A-AR
expression in PCa progression. Here, we found that cav-1 and
a1A-AR were strongly expressed in luminal, invasive epithelial cells
in stage III PCa (Figure 6A, b, cancerous acinus). Furthermore, in
hyperplastic tissues cav-1 and a1A-AR immunostaining was
present in the simple lining of cytokeratin 18-positive-acinar
epithelium and in the fibromuscular stroma (Figure 6A, b,
hyperplastic acinus). The majority of the normal regions of the
samples expressed low levels of cav-1 and a1A-AR in apical
epithelial cells and the presence of the two proteins was mostly
observed in the stroma (Figure 6A, b, normal acinus). Overall,
these results demonstrated elevated expressions of cav-1 and a1A-
AR in advanced PCa epithelial cells, more numerous and invasive
in these conditions than in BPH.
Finally, we were interested in assessing the mRNA levels of a1A-
AR and cav-1 in a series of cancerous and hyperplastic human
prostate samples. We analyzed six PCa samples obtained from
patients in hormone-refractory phase and characterized as
androgen-independent and six BPH samples (Figure 6B, a).
Relative quantification of a1A-AR and cav-1 mRNA levels as
compared to GAPDH internal control was quite promising
(Figure 6B, b). We found average mRNA levels of a1A-AR and
cav-1 more elevated in androgen-independent PCa samples than
in BPH (Figure 6B, b, black and hatched grey columns).
Noticeably, cytokeratin 18 mRNA was more abundant in
androgen-independent cancer samples than BPH, in agreement
with our previous observations in immunofluorescence. Finally, we
noticed that basal epithelial cells’ marker cytokeratin 14 mRNA
levels did not present any variations between androgen-indepen-
dent prostate cancer and BPH (except for sample C2 for which no
information is available to allow an explanation for its non-
detection). Our data strongly suggest that a1A-AR may be
associated with androgen-independent PCa epithelial cells and
advanced stage PCa just like cav-1. Regardless of internal
variability of hyperplastic and cancerous samples (related to
factors such as patients’ age, progression of disease, treatment) we
underlined significant elevated mRNA levels of a1A-AR and cav-1
in androgen-independent cancer compared to BPH. We propose
that their simultaneous expression could account in part for the
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PLoS ONE | www.plosone.org 9 September 2009 | Volume 4 | Issue 9 | e7068Figure 5. PHE enhances TG-induced apoptosis resistance in DU145 cells also via bax activation. Representative immunofluorescence of
(A) DU145, (B) DushCTL and (C) Dushcav-1 cells in (a) non-treated conditions, (b) 10 mM TG for 48 h, (c) 10 mM PHE 3-day pretreatment (d) with the
presence of 1 mM PRA, followed by 10 mM TG for 48 h showing the presence of activated Bax recognised by the anti-bax (6A7) antibody. The
presence of cells in the observation field is indicated by DAPI-stained nuclei. Bar, 50 mm.
doi:10.1371/journal.pone.0007068.g005
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PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e7068Figure 6. a1A-AR and cav-1 differential expressions in normal, cancerous and hyperplastic human prostate. (A)(a) Western blot
showing the expression of a1A-AR in DU145 cells transfected with two siRNA against a1A-AR (siADR1A-1 and siADR1A-2) and control siRNA (siCTL).
Numbers above gels indicate relative densitometry assessed on actin expression. (b) Representative immunofluorescence of normal prostate acinus
showing the presence of the apical epithelial marker cytokeratin 18 (cytk 18, green) and a1A-AR or cav-1 fluorescence (red); Bar, 50 mm. Star indicates
the acinus lumen and white arrowhead fibromuscular stroma. The middle left panel shows representative stage III cancerous acinus. Typically,
cancerous apical epithelial cells detected with cytokeratin 18 (green) have completely invaded the lumen and express both a1A-AR and cav-1 (red);
Bar, 50 mm. The middle right panel shows a section of a representative hyperplastic acinus where the lumen (star) is enlarged; Bar, 20 mm. (B)(a)
Agarose gel showing the expression of a1A-AR (178 pb), cav-1 (220 pb), cytokeratin 18 (241 pb) and cytokeratin 14 (210 pb) amplicons in six different
prostatic androgen-independent carcinoma tissues and six different benign hyperplasia tissues. A no-template control was also run with the PCR
samples where cDNA was replaced with water (H2O). A 1-kilobase DNA ladder (MW (bp)) was used as a DNA size marker. GAPDH (236 pb) was used as
an internal control. (b) Ratios of mean mRNA quantities of a1A-AR, cav-1, cytokeratin 18 (cytk 18) and 14 (cytk 14) as compared to GAPDH in
androgen-independent (AI) cancer (black columns) and hyperplastic samples (grey hatched columns). Plots are the average cumulative data
(mean 6 SEM) of six samples by condition. Statistical analysis used the t test; *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0007068.g006
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epithelial cells.
PHE protection from TG-induced apoptosis in DU145
cells involves activation of the ERK1/2 signalling pathway
It is now well established that ERKs are overexpressed in
advanced stage prostate cancer and play a significant role in
prostate tumorigenesis [50,51]. This family of serine/threonine
kinases is involved in transmitting signals regulating cell survival
and growth [52]. Recently, is has been shown that the a1B-AR
activates ERK in submandibular gland cells via a mechanism
dependent of membrane microdomain integrity [53]. In the
present study, we were interested in assessing PHE-induced
activation of ERK1/2 and the potential involvement of this
signalling pathway in the TG-induced apoptosis resistance
described in DU145 cells. A 30 min treatment by 10 mM PHE
induced activation by phosphorylation of ERK1/2 (p44/p42
MAPK) (Figure 7A, a and b). We used the specific inhibitor of
ERK1/2 phosphorylation, 10 mM PD98059, which drastically
decreased amount of activated ERK1/2 (Figure 7A, a and b). In
order to demonstrate the involvement of ERK1/2 in the TG-
induced apoptosis resistance in DU145 cells, we assessed PARP
cleavage, indicating induction of apoptosis (Figure 7B). Interest-
ingly, after simultaneous pretreatment of DU145 cells by 10 mM
PHE and 10 mM PD98059 followed by 10 mM TG, we detected a
2-fold increase of cleaved PARP (89 kD) as compared to PHE
alone followed by TG, strongly suggesting increased apoptosis in
the presence of PD98059 (Figure 7B, a, lanes 4 and 5, b). As
previously described (Figure 4B, a and d) TG alone induced a
higher level of PARP cleavage as compared to PHE-pretreatment
conditions (lanes 6 and 4). It should also be noted that PARP
cleavage was similar in TG treatment conditions alone or in the
presence of PD98059 and that PHE and/or PD98059 alone did
not induce PARP cleavage (lanes 2, 3 and 8).
Figure 7. TG-induced apoptosis resistance in DU145 cells is mediated by ERK1/2. (A)(a) Western blot showing expression of phosphorylated
p44/p42 MAPK (ERK1/2) in non-treated cells (CTL), 30 min treatment by 10 mM PHE (PHE 30 min) and simultaneous treatment by 10 mM PHE and10 mM
PD98059 (PHE+PD98059). (b) Expression of phospho-p44 and phospho-p42 MAPK is assessed on total p44/p42 MAPK in DU145 cells. (B)(a) Western blot
showing expression of PARP full length fragment (116 kD) and cleaved PARP (89 kD) in the following treatment conditions: non-treated (CTL), 30 min or
72 h treatment by 10 mM PHE (PHE 30 min, PHE 72 h), pre-treatment by PHE alone or in the presence of 10 mM PD98059 followed by 48 h treatment by
10 mMT G( P H E +TG and PHE+PD98059+TG), 48 h treatment by 10 mM TG alone (TG) or preceded by 10 mM PD98059 pre-treatment (PD98059+TG) and
10 mM PD98059 treatment alone. (b) Expression of cleaved PARP is assessed on calnexin used as internal control for PHE+TG and PHE+PD98059+TG
treatment conditions. Plots are the average cumulative data (mean 6 SEM) of three experiments. Statistical analysis used the t test; ***, p,0.001.
doi:10.1371/journal.pone.0007068.g007
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Various locally produced and circulating factors maintain
prostate cancer growth by acting through cellular receptors.
Increasing evidence supports the involvement of GPCR in
neoplastic transformation of the prostate [54,55]. Moreover,
cancerous prostate expresses increased levels of GPCR and their
ligands (for example bradykinin, endothelin and their correspond-
ing receptors) [56,57] suggesting that GPCR signalling may always
be ‘‘switched on’’ therefore contributing to the initiation and
progression of the disease.
A growing number of recent data has shown the involvement of
a1A-AR in human prostate pathology [58,59]. Further lines of
evidence have demonstrated that a1A-AR and its effector proteins
are differentially distributed in surface caveolae of cardiac cells
[15,16]. Caveolae and cav-1 have been described to play
prominent roles in various human disease phenotypes including
cancer (for reviews [18,60]). Interestingly, the expression of cav-1
has been identified to be closely associated with PCa malignant
progression and highly expressed in androgen-independent cells
[61,20,49].
Despite the above findings, the precise surface localization of the
a1A-AR in androgen-independent PCa epithelial cells and its
functional role in the proliferation and survival of these cells
remain unknown. The present study is the first to demonstrate the
localization of a1A-AR in caveolae of the androgen-independent
PCa epithelial cells DU145. Our results from the exploration of
the lipid-protein contents of purified DRM from these cells were
particularly revealing. Noticeably, we provide evidence of
significant increase in DRM lipids upon agonist stimulation of
the a1A-AR. We propose that this elevated content of raft-specific
lipids consequently leads to alterations of DRM density as it is
known that high lipid composition causes floating of membranes to
lower density fractions after centrifugation [62]. Our results after
dot blot analysis strongly suggest that a1A-AR and cav-1 content is
accordingly distributed toward lower density fractions.
Furthermore, lipid composition alterations may be explained by
coalescence of cav-1-containing membranes. In agreement with
this suggestion, we observed a remarkable surface membrane
reorganisation and formation of a great number of cav-1-rich
invaginations following a1A-AR stimulation. It is well established
that caveolae are formed by the polymerisation of caveolins,
leading to the clustering and invagination of a subset of
sphingolipid/cholesterol-rich membrane domains [36]. The traf-
ficking of intracellular caveolin-containing membranes and their
fusion with the plasma membrane could supply domains with cav-
1 and lipids for caveolae formation. Besides it has been described
that lipid redistribution in the plasma membrane may modify the
biophysical properties of microdomains and regulate signalling
pathways [63]. The exact relationship between microdomain
composition, density and size is not well established to date. What
is known though from previously published data on lipid model
systems is that the size of lipid rafts depends on the lipid
membrane composition [33,34] strongly implying that cells could
tune their membrane composition to create or destroy domains
[64].
A large body of work indicates that cav-1 expression is essential
for caveolae formation and function [65,66]. Moreover, it has
been demonstrated in cardiac cells that caveolae integrity regulates
a1A-AR signalling [67,68]. It is essential to note that all a1A-AR
may not necessarily be associated to caveolae. In order to study the
importance of the caveolar localisation of a1A-AR, we examined
its functional role in the presence and absence of cav-1. We
demonstrated that agonist stimulation of the a1A-AR enhanced
resistance to reticular stress-induced apoptosis in DU145 cells
through the Bax and the caspase-3 pathway. Importantly, we
found that cells underexpressing cav-1 showed no resistance to
TG-induced apoptosis, thus implying the necessity of caveolae
integrity in this process.
Our results strongly suggest that a1A-AR signalling in DU145
cells contributes to their resistance to TG-induced apoptosis via
caveolae. Additionally, our data add to the growing evidence that
cav-1 promotes survival and growth of PCa cells [21,47,22]. The
elevated expression of a1A-AR and cav-1 in DU145 cells may
contribute to favouring a1A-AR signalling pathway via caveolae
amplifying the effects on the survival of these cells.
To date, no relevant data describes a1A-AR expression
variations according to prostate pathological state. Our study
was innovative in the investigation of both a1A-AR and cav-1
expression in normal, cancerous and BPH samples. We show that
the elevated expression of a1A-AR in prostate epithelial cells is
correlated with prostate pathological progression. During
prostate cancer, the organ’s architecture is greatly compromised,
characterized among others, by proliferation of epithelial cells
and invasion of prostate ducts and acini [69]. Our immunohisto-
fluorescent study provides evidence of numerous cytokeratin-18-
positive (apical epithelial) cells invading acini in advanced PCa
samples highly expressing cav-1 and a1A-AR as compared to
normal or hyperplastic prostate. Accordingly, we demonstrated
increased mRNA levels of cytokeratin-18, a1A-AR and cav-1 in
androgen-independent PCa samples as compared to BPH
samples. In agreement with previously published data our results
propose that the role of a1A-AR in BPH is related to its presence
in the fibromuscular stroma [45,70,71]. Further, elevated
expression of both cav-1 and a1A-AR in advanced stage PCa
epithelial cells provide a strong rationale for the understanding of
the significance of a1A-AR signalling in androgen-independent
PCa.
Previous work from our laboratory has demonstrated that TG-
induced apoptosis as well as apoptosis resistance induced by EGF
in DU145 cells are mechanisms dependent of intracellular Ca
2+
signalling [72]. We have observed that PHE treatment has no
affect on the intracellular Ca
2+ concentration (data not shown).
This observation strongly suggests that resistance to TG-induced
apoptosis in DU145 by PHE does not involve the Ca
2+ signalling
pathway. a1A-AR signalling is complex and various lines of
evidence demonstrate that a1A-AR stimulation can activate a
variety of signalling pathways depending on cell type, receptor
expression and agonist concentration [73,74]. It has been
previously described, in cardiomyocytes, that a1A-AR activate
ERK-related survival pathways [75]. We have revealed, for the
first time, the involvement of the ERK1/2 MAPK pathway in the
apoptosis resistance function of the a1A-AR in DU145 androgen-
independent prostate cancer cells. Interestingly, it has been
demonstrated that human prostate biopsies have increased levels
of activated ERKs in malignant tissues as compared to those in
benign specimens [50,51].
In conclusion, we demonstrate that caveolae of androgen-
independent prostate cancer cells DU145 are involved in the
apoptosis resistance induced by the a1A-AR. Our data show that
caveolae integrity is necessary for a1A-AR function in these cells.
This study reveals that a1A-AR and cav-1 expressions are
positively correlated with the pathological state of human prostate
and are highly expressed in advance PCa tissue samples. Our data
strongly suggest that the protective function of the a1A-AR via
caveolae described in DU145 cells, may contribute in synergy with
other factors, to the apoptosis resistance mechanisms of PCa cells
and enhancement of their survival.
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Figure S1 Representative cell cycle profiles of propidium iodide
(PI)-stained (A) DU145, (B) DUshCTL and (C) DUshcav-1 cells
obtained by flux cytometry as described in the ‘‘Methods’’ section.
(a) Non-treated cells, (b) cells treated by 10 mM TG for 48 h, cells
pre-treated for three days by 10 mM PHE alone (c), or
simultaneously with 1 mM PRA (d), followed by 10 mM TG for
48 h. In all cases, TG treatment induces an increase in the
percentage of cells in SubG1 phase, thus apoptotic cells (A, a and
b; B, a and b; C, a and b). In PHE pre-treatment conditions in
DU145 and DUshCTL cells induced a decrease in the percentage
of cells in SubG1 phase as compared to TG alone (A, c; B, c). PHE
pre-treatment had no effect on the percentage of DUshcav-1 cells
in SubG1 phase (C, b and c). The anti-apoptotic effect of PHE was
counteracted by PRA in DU145 (A, d) and DUshCTL cells (B, d)
where a higher number of apoptotic cells was observed as
compared to pretreatment by PHE alone, but this was not
observed in Dushcav-1 cells (C, d). It should be noted that PHE
(D, 2) or PRA (D, 3) alone had no effect on the cell cycle phases as
compared to control DU145 cells (D, 1) (as well as DushCTL and
Dushcav-1).
Found at: doi:10.1371/journal.pone.0007068.s001 (0.56 MB
PDF)
Figure S2 Representative examples of Hoechst-stained (A)
DU145 wild-type, (B) DUshCTL and (C) DUshcav-1 cells. Cells
were (a) non-treated, (b) treated by 10A ˆmM TG for 48 h, (c) pre-
treated by 10A ˆmM PHE for 3 days followed by 48 h 10A ˆmMT G
or (d) pre-treated simultaneously by 10A ˆmM PHE and 1A ˆmM PRA
for 3 days followed by 48 h 10A ˆmM TG (as described in the
‘‘Methods’’ section). Cells fixed in ice-cold methanol (15 min) were
stained by 4A ˆmg/ml Hoechst 33528 (Sigma) for 30 min. Stained
nuclei were observed at 435 nm using a fluorescence microscope
(AxioImager, Zeiss). A total of 500 stained nuclei per condition
(three slides per condition) were considered and typical apoptotic
figures (chromatin condensation and nuclear fragmentation) were
counted, indicated here by the white arrowheads. In (A), (B) and
(C) we observed a higher level of apoptosis in TG-treated
conditions (b) as compared to (a) non-treated conditions. A three
day PHE pre-treatment followed by TG induced a lower number
of apoptotic cells (A, c) and (B, c) than TG alone (A, b and B, b).
This effect was not observed in DUshcav-1 cells (C) where the
number of apoptotic cells was almost the same in b, c and d. The
anti-apoptotic effect of PHE was counteracted by PRA in DU145
(A, d) and DUshCTL cells (B, d) where a higher number of
apoptotic cells was observed as compared to pretreatment by PHE
alone. These results are in agreement with our observation of
percentage of apoptotic cells in the SubG1 cell cycle phase
(Figure 4A, b).
Found at: doi:10.1371/journal.pone.0007068.s002 (2.59 MB TIF)
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